Report of safety of pulse dosing of lapatinib with temozolomide and radiation therapy for newly-diagnosed glioblastoma in a pilot phase II study

Epidermal growth factor receptor (EGFR) mutations are commonly observed in Glioblastoma (GBM) and have long posed as a target for new therapies. Trials involving erlotinib have shown mixed results, likely owing to a mechanism of the mutation that may instead favor other EGFR inhibitors, such as lapa...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:J Neurooncol
Main Authors: Yu, Andrew, Faiq, Nadia, Green, Stacey, Lai, Albert, Green, Richard, Hu, Jethro, Cloughesy, Timothy F., Mellinghoff, Ingo, Nghiemphu, P. Leia
Formato: Artigo
Idioma:Inglês
Publicado: 2017
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC6135089/
https://ncbi.nlm.nih.gov/pubmed/28669012
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s11060-017-2533-6
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares